Form DEFC14A - Definitive proxy statement, contested solicitations:
SEC Accession No. 0001193125-16-550020
Filing Date
2016-04-21
Accepted
2016-04-21 13:57:13
Documents
1
Effectiveness Date
2016-04-21

Document Format Files

Seq Description Document Type Size
1 DEFC14A d52279ddefc14a.htm DEFC14A 425475
  Complete submission text file 0001193125-16-550020.txt   427360
Mailing Address 19820 NORTH CREEK PARKWAY SUITE 201 BOTHELL WA 98011
Business Address 19820 NORTH CREEK PARKWAY SUITE 201 BOTHELL WA 98011 425-686-1500
ONCOGENEX PHARMACEUTICALS, INC. (Filed by) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFC14A
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 19820 NORTH CREEK PARKWAY SUITE 201 BOTHELL WA 98011
Business Address 19820 NORTH CREEK PARKWAY SUITE 201 BOTHELL WA 98011 425-686-1500
ONCOGENEX PHARMACEUTICALS, INC. (Subject) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFC14A | Act: 34 | File No.: 033-80623 | Film No.: 161583699
SIC: 2835 In Vitro & In Vivo Diagnostic Substances